Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir Prophylaxis vs Preemptive Strategy in Kidney Transplant
NCT06341686Phase 3Not yet recruiting
- Sponsor
- Hospital do Rim e Hipertensão
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Hospital do Rim e Hipertensão. Primary endpoint: Incidence of CMV syndrome or disease at 6 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06341686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341686.